Canada's OceanaGold Q2 gold output rises on higher production at Haile
Reuters2026/08/05 21:23
Overview
Canada-based gold and copper miner's Q2 revenue rose, gold output up 7% from prior quarter
Net profit for Q2 was $222 mln, with strong free cash flow and no debt
Company returned $78 mln to shareholders via dividends and share buybacks in Q2
Outlook
Oceanagold maintains 2026 full-year gold production guidance at 520-590 koz
Company expects consolidated AISC to be near upper end of $1,750-$1,900/oz guidance range
Oceanagold forecasts higher gold production and lower AISC in H2 2026
Result Drivers
HIGHER GOLD PRODUCTION - Co said gold output rose 7% from prior quarter, driven by increased production at Haile
PRODUCTION WEIGHTED TO END OF QUARTER - Revenue reflected gold sales weighted towards the end of the quarter as production increased at Haile
HIGHER COSTS - Co said AISC rose due to labor cost inflation, continued investment in maintenance and reliability, unhedged energy costs and lower silver by-product credits
Company press release: ID:nPn9qWggZa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Revenue |
Miss |
$647 mln |
$767 mln (1 Analyst) |
Q2 Net Income |
|
$222 mln |
|
Q2 Operating Cash Flow |
|
$314 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the gold peer group is "buy"
Wall Street's median 12-month price target for OceanaGold Corp is C$56.00, about 58.8% above its August 4 closing price of C$35.27
The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 7 three months ago
Reuters Recommended Reads
Aug 4 - SSR Mining Q2 adjusted EPS misses analyst expectations
Aug 4 - Mexico's Fresnillo H1 revenue jumps on higher precious metal prices; raises dividend
Aug 4 - Hecla Mining Q2 revenue falls sequentially on lower metal prices
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
